News
Dr. Marty Makary, FDA commissioner, joins 'Squawk Box' to discuss what hindsight tells science about the best route to take ...
The letters, many of which were already available online, detail why the regulators initially declined to approve some drugs.
The Food and Drug Administration will consider drug affordability when granting companies new vouchers that speed up ...
“We want to focus on food. People forget that the ‘F’ in FDA stands for food,” Makary said. Makary noted that the processed ...
Dr. Marty Makary, FDA commissioner, joins 'Squawk Box' to discuss what hindsight tells science about the best route to take post-Covid, changes to the Vaccine Advisory Committee and much more.
FDA Commissioner Marty Makary suggests his agency may expedite drug reviews for manufacturers reducing U.S. prices to global ...
The lawsuit alleges that a decision in May to remove COVID-19 vaccines from the federal list of recommended vaccines for ...
Food and Drug Administration Commissioner Marty Makary said his agency may fast-track new drugs from pharmaceutical companies that “equalize” the cost of their medicines between the US and other ...
Unlike Drs. Adam Cifu and John Mandrola, I do not constantly boast of my "nuance" or claim to be a master of "clinical ...
Cybin has made steady progress but faces major hurdles, with its stock swayed by sector sentiment. Read why CYBN stock is upgraded to hold.
The FDA has released an “initial batch“ of more than 200 complete response letters (CRLs) in efforts to boost transparency. | ...
By disclosing the CRLs, the FDA provides an insight into common pitfalls that sponsors must rectify to gain approval.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results